STRATA Skin Sciences (SSKN) Q4 2024 Earnings Call March 27, 2025 09:57 PM ET Company Participants Louie Toma - Managing DirectorDolev Rafaeli - President, CEO & Vice-ChairmanJohn Gillings - VP of FinanceJeffrey Cohen - MD - Equity Research Conference Call Participants Jeremy Pearlman - Equity Analyst Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the Strata Sciences Inc. Fourth Quarter and Year End twenty twenty four Financial Results and Corporate Update Conference ...

Braze, Inc. (NASDAQ:BRZE) Q4 2025 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Christopher Ferris - Head of IR William Magnuson - Co-Founder and CEO Isabelle Winkles - CFO Conference Call Participants Ryan MacWilliams - Barclays Arjun Bhatia - William Blair David Hynes - Canaccord Genuity Gabriela Borges - Goldman Sachs Brent Bracelin - Piper Sandler Brian Peterson - Raymond James Derrick Wood - TD Cowen Nick Altmann - Scotiabank Scott Berg - Needham Taylor McGinnis - UBS Michael ...

TAT Technologies (TATT) Q4 2024 Earnings Call March 27, 2025 09:42 PM ET Company Participants Matt Chesler - PartnerIgal Zamir - CEO & PresidentEhud Ben-Yair - Chief Financial Officer Conference Call Participants Josh Sullivan - Managing Director & Equity Research AnalystNone - Analyst Matt Chesler Good day, ladies and gentlemen. Thank you for standing by. Welcome to TAT Technologies, fourth quarter two thousand and twenty four earnings conference call. Please note that today's conference call may be record ...

HireQuest (HQI) Q4 2024 Earnings Call March 27, 2025 09:33 PM ET Company Participants John Nesbitt - Investor RelationsRick Hermanns - President and Chief Executive OfficerSteve Crane - CFOKevin Steinke - Managing DirectorKeegan Cox - Research Associate Operator Greetings. Welcome to the Hire Quest Inc. Fourth Quarter and Year End twenty twenty four Earnings Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this con ...

The Beachbody Company, Inc. (NYSE:BODI) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Bruce Williams ??? Managing Director-ICR Mark Goldston ??? Executive Chairman Carl Daikeler ??? Co-Founder and Chief Executive Officer Brad Ramberg ??? Interim Chief Financial Officer Conference Call Participants Susan Anderson ??? Canaccord Genuity JP Wollam ??? ROTH Capital Partners Gowshi Sri ??? Singular Research Operator Good afternoon. Thank you for attending today’s Beachbody Compan ...

VirTra, Inc. (NASDAQ:VTSI) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants John Givens ??? Chief Executive Officer Alanna Boudreau ??? Chief Financial Officer Conference Call Participants Jaeson Schmidt ??? Lake Street Capital Markets Richard Baldry ??? ROTH Capital Partners Operator Good afternoon, and welcome to VirTra’s Fourth Quarter and Full Year 2024 Earnings Call. My name is Diego, and I will be your operator for today’s call. Joining us for today’s presentation are th ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Max Gadicke - Precision AQ, Investor Relations David Dodd - Chairman, President & CEO Mark Reynolds - Chief Financial Officer Kelly McKee - Chief Medical Officer John Sharkey - Vice President, Business Development Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Robert LeBoyer - Noble Capital Markets Laura Suriel - Alliance Global Partners Operator Good afternoon. And welcome ...

Financial Data and Key Metrics Changes - For Q4 2024, total revenue grew by 40% year over year to $33.2 million, with adjusted net income increasing by 126% to $13.4 million and adjusted EBITDA rising by 51% to $16.6 million [9][10][24] - For the full year 2024, total revenue increased by 69% to $111.9 million, adjusted net income grew by 58% to $46.5 million, and adjusted EBITDA rose by 57% to $61.6 million [10][24][29] - Adjusted EBITDA margin for Q4 was 50%, compared to 47% in the prior year, while for the full year, it was 55%, down from 59% [27][29] Business Line Data and Key Metrics Changes - The company completed two strategic acquisitions, Carlisle Management Company and FCF Advisors, adding approximately $2.6 billion in assets under management [12][13] - Policy originations increased by 63% to 1,034 in 2024, with capital deployed exceeding $344 million [10][19] Market Data and Key Metrics Changes - The company reported a strong liquidity position with cash and cash equivalents of $128.8 million and outstanding long-term debt of $342.4 million as of December 31, 2024 [28] - The company anticipates a strong 2025, projecting adjusted net income between $70 million and $78 million, implying growth of 51% to 68% [11][29] Company Strategy and Development Direction - The company aims to solidify its position as a leader in the alternative asset management space, leveraging proprietary technology and data to capture market opportunities [21][32] - The rebranding to Abacus Global Management reflects the company's evolution and global market presence, enhancing its offerings to institutional investors [16][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth opportunities ahead, citing a favorable market environment for both policy origination and investor interest in unique assets [66][72] - The company is well-positioned for 2025, with a focus on integrating acquisitions and expanding its asset management capabilities [19][29] Other Important Information - The company raised $181.7 million in additional equity and secured a $150 million debt-financing facility to support growth initiatives [19][20] - The company has initiated a new ETF, the Abacus FCF Small Cap Leaders ETF, and reduced management fees across its ETFs [15][19] Q&A Session Summary Question: Key swing factors in guidance assumptions - Management clarified that the guidance range does not depend on a full draw of the remaining $50 million on the revolver, emphasizing strong origination and integration of asset management [34][36] Question: Update on direct channel metrics post-advertising shift - Management confirmed that advertising was not paused but targeted to non-swing states, resulting in continued positive impacts on policy origination [37][39] Question: Deployment of capital from recent equity and debt offerings - Management indicated significant deployment of capital in Q4 and a strong position for Q1, with expectations for continued positive results [42][44] Question: Strategy for holding policies on the balance sheet - Management stated that policies on the balance sheet are expected to hover around $370 million to $450 million, with a target of two turns per year on average [50][52] Question: Update on the carrier buyback program - Management reported ongoing expansion of the carrier buyback program and positive expectations for 2025 [57][60] Question: Changes in behavior of individuals life settling policies - Management noted that market volatility tends to increase interest in liquidity options, positively impacting origination [61][66] Question: Year-end AUM at Carlisle and FCF - Management expressed optimism about AUM growth for both entities, citing strong interest and favorable market conditions [69][72]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $22.5 million, an increase of 11% compared to $20.3 million in Q4 2023 [22][8] - U.S. NeuroStar Advanced Therapy System revenue was $3.8 million with 46 systems shipped [22][23] - U.S. treatment session revenue decreased by 14% year-over-year to $12.9 million, primarily due to the removal of Greenbrook treatment session revenues [23] - Gross margin decreased to 66.2% from 77.6% in the prior year, a decline of 1,140 basis points [24] - Operating expenses increased by 28% to $25.8 million compared to $20.2 million in Q4 2023 [24] - Net loss for Q4 was $12.1 million or $0.33 per share, compared to a net loss of $5.4 million or $0.19 per share in the prior year [25] - EBITDA was negative $10.5 million, including approximately $10.6 million in non-recurring expenses [25] Business Line Data and Key Metrics Changes - NeuroStar system revenue was $3.8 million, with 46 systems shipped [22][23] - U.S. clinic revenue, representing Greenbrook's revenues post-acquisition, was $4.4 million [23] Market Data and Key Metrics Changes - The company received FDA clearance for the NeuroStar system to treat adolescents, expanding the total addressable market for major depressive disorder [18] - There was an 18% increase in customer sites treating adolescent patients, now including more than half of the customer base [19] Company Strategy and Development Direction - The company aims to rapidly scale the Better Me Provider Program across its customer base, targeting over 500 sites by year-end 2025 [34] - The acquisition of Greenbrook TMS is seen as a transformative step, creating a leading TMS supplier and provider in the U.S. [14] - The company has identified significant cost synergies, capturing over 90% of the identified $22 million in annualized cost synergies by the end of 2024 [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity by Q3 2025, supported by enhanced scale and operational efficiencies [41] - The company anticipates full-year revenue in the range of $145 million to $155 million for 2025, with a focus on improving utilization and expanding the SPRAVATO rollout [29][73] Other Important Information - The company raised $18.9 million in capital to support growth initiatives [10][27] - The Better Me Provider Program has shown that practices implementing its standards treat three times more patients per site per quarter compared to those not in the program [13] Q&A Session Summary Question: Update on Greenbrook integration and BMP implementation - Management indicated ongoing training and implementation of BMP standards across clinics, with changes expected to continue throughout the year [46] Question: Guidance on revenue and operating expenses - The revenue guidance of $145 million to $155 million is based on contributions from both Neuronetics and Greenbrook, with a focus on successful program execution [51] Question: Margin profile and improvement opportunities - Management acknowledged opportunities for margin improvement, particularly by eliminating underperforming clinics and optimizing operations [62] Question: SPRAVATO rollout and revenue assumptions - The majority of growth is expected to come from SPRAVATO, with plans to increase the number of clinics offering it [75] Question: Capital outlay for SPRAVATO rollout - The capital expenditure for supporting the SPRAVATO rollout is minimal, primarily involving inventory commitments [84] Question: Current productivity metrics and future expectations - Current average treatments per day per system at Greenbrook is four, with expectations to increase to five or six by the end of 2025 [88]

Financial Data and Key Metrics Changes - As of December 31, 2024, the company's cash and cash equivalents totaled approximately $20 million, which is expected to fund operations into the fourth quarter of 2025 [36] - The company is actively pursuing options to fund the CLS-AX Phase 3 program, including potential partnerships with third parties [36] Business Line Data and Key Metrics Changes - The company reported positive results from the ODYSSEY Phase 2b wet AMD clinical trial, leading to a successful end of Phase 2 meeting with the FDA regarding planned Phase 3 activities for CLS-AX [7][29] - The SCS Microinjector has been used for over 15,000 suprachoroidal injections, indicating strong interest from retinal specialists and pharmaceutical companies [6] Market Data and Key Metrics Changes - The wet AMD market represents over $12 billion in annual sales, with the company positioning CLS-AX as a maintenance treatment to capture a significant share [31] - The company’s partner, Arctic Vision, achieved regulatory milestones in the Asia-Pacific region, with product approvals in Australia and Singapore, and a new drug application under review in China [9] Company Strategy and Development Direction - The company aims to maximize the commercial potential of CLS-AX through a pivotal Phase 3 program designed to reduce regulatory risk and enhance market competitiveness [29][30] - The strategy includes targeting treatment-naive patients to potentially expand the commercial value of CLS-AX [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the Phase 3 trial design and its potential to demonstrate the efficacy of CLS-AX, emphasizing the importance of reducing variability in patient selection [29][84] - The company is optimistic about the broad applicability of suprachoroidal delivery in treating serious retinal diseases, with ongoing evaluations of small molecules for geographic atrophy [32] Other Important Information - The company is the only TKI in development with multi-dosing data from its Phase 2b trial and the ability to re-dose before six months, which is seen as a significant differentiator [29] - The company is preparing for participation in upcoming healthcare conferences to further engage with stakeholders [36] Q&A Session Summary Question: How might the amendments to the planned Phase 3 improve results from Phase 2? - Management believes that excluding patients with higher disease variability will lead to better results in the general population [45][46] Question: How long will it take to enroll the treatment-naive population? - Enrollment is expected to take around 12 months, based on recent trials [48] Question: What is the estimated cost of the Phase 3 program? - While specific costs were not disclosed, similar Phase 3 trials have been around $55 million to $60 million [55] Question: How will the redosing criteria work? - Redosing will rely on OCT biomarkers, with a focus on intraretinal fluid, and will be distinct from rescue criteria [95][100] Question: Will the inclusion criteria impact enrollment speed? - Management anticipates minimal impact on enrollment speed, estimating that less than 10% of patients would be rejected based on the new criteria [84]